NZ594452A - Anti-mst1r antibodies and uses thereof - Google Patents

Anti-mst1r antibodies and uses thereof

Info

Publication number
NZ594452A
NZ594452A NZ594452A NZ59445210A NZ594452A NZ 594452 A NZ594452 A NZ 594452A NZ 594452 A NZ594452 A NZ 594452A NZ 59445210 A NZ59445210 A NZ 59445210A NZ 594452 A NZ594452 A NZ 594452A
Authority
NZ
New Zealand
Prior art keywords
antigen
binding region
mst1r
chain cdrs
antibody
Prior art date
Application number
NZ594452A
Other languages
English (en)
Inventor
Reimi Kawaida
Toshiaki Ohtsuka
Toshinori Agatsuma
Philip Rodley
Sandra Miller
Ulrike Schubert
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of NZ594452A publication Critical patent/NZ594452A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ594452A 2009-02-10 2010-02-10 Anti-mst1r antibodies and uses thereof NZ594452A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15141109P 2009-02-10 2009-02-10
PCT/JP2010/052479 WO2010093055A1 (en) 2009-02-10 2010-02-10 Anti-mst1r antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ594452A true NZ594452A (en) 2013-01-25

Family

ID=42227811

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594452A NZ594452A (en) 2009-02-10 2010-02-10 Anti-mst1r antibodies and uses thereof

Country Status (18)

Country Link
US (1) US9403909B2 (https=)
EP (1) EP2396084B1 (https=)
JP (1) JP5714511B2 (https=)
KR (1) KR101745025B1 (https=)
CN (1) CN102438702B (https=)
AU (1) AU2010214301B2 (https=)
BR (1) BRPI1007979A2 (https=)
CA (1) CA2752136C (https=)
CO (1) CO6420322A2 (https=)
ES (1) ES2583281T3 (https=)
IL (1) IL214527A0 (https=)
MX (1) MX2011008456A (https=)
NZ (1) NZ594452A (https=)
RU (1) RU2534890C2 (https=)
SG (2) SG2014009195A (https=)
TW (1) TWI480050B (https=)
WO (1) WO2010093055A1 (https=)
ZA (1) ZA201105725B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356749B (es) * 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
EP3504244A4 (en) 2016-08-26 2020-08-19 Agency for Science, Technology and Research MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
CA2566647A1 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
US20060073256A1 (en) * 2004-06-15 2006-04-06 Frederic Destaillats Self-foaming liquid creamers and processes
JP2008512352A (ja) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
UY31478A1 (es) * 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
MX2010008025A (es) * 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.

Also Published As

Publication number Publication date
EP2396084B1 (en) 2016-05-11
AU2010214301A1 (en) 2011-09-01
US9403909B2 (en) 2016-08-02
KR20110117677A (ko) 2011-10-27
WO2010093055A1 (en) 2010-08-19
TW201036635A (en) 2010-10-16
SG173196A1 (en) 2011-08-29
IL214527A0 (en) 2011-09-27
KR101745025B1 (ko) 2017-06-20
US20120034215A1 (en) 2012-02-09
HK1164193A1 (zh) 2012-09-21
CO6420322A2 (es) 2012-04-16
RU2534890C2 (ru) 2014-12-10
RU2011137405A (ru) 2013-03-20
TWI480050B (zh) 2015-04-11
JP5714511B2 (ja) 2015-05-07
EP2396084A1 (en) 2011-12-21
ZA201105725B (en) 2012-04-25
MX2011008456A (es) 2011-09-26
AU2010214301B2 (en) 2016-11-10
SG2014009195A (en) 2014-04-28
BRPI1007979A2 (pt) 2017-10-03
ES2583281T3 (es) 2016-09-20
CN102438702A (zh) 2012-05-02
JP2012517223A (ja) 2012-08-02
CA2752136A1 (en) 2010-08-19
CN102438702B (zh) 2016-03-02
CA2752136C (en) 2016-03-15

Similar Documents

Publication Publication Date Title
NZ594682A (en) Fully human antibodies specific to cadm1
AR083747A1 (es) Anticuerpos anti-il-23
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
NZ605980A (en) Anti-fap antibodies and methods of use
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ626269A (en) Anti-phf-tau antibodies and their uses
MX383543B (es) Anticuerpo anti-calicreina-2 humanizado.
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
NZ706377A (en) Il-6 antagonists and uses thereof
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
AR109715A1 (es) Anticuerpos anti-cd27
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ610734A (en) Human antibodies to the glucagon receptor
NZ610091A (en) Antibodies
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
NZ712765A (en) Antibodies that bind csf1r
NZ586053A (en) Anti-vegf antibody compositions and methods
NZ611428A (en) Novel modulators and methods of use
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
AR082163A1 (es) Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 FEB 2017 BY CPA GLOBAL

Effective date: 20131227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 FEB 2018 BY CPA GLOBAL

Effective date: 20161230

LAPS Patent lapsed